TSHA NASDAQ
Taysha Gene Therapies, Inc.
1W: -0.9%
1M: -17.9%
3M: -27.4%
YTD: -11.8%
1Y: +45.6%
3Y: +55.9%
5Y: -76.9%
$4.63
-0.11 (-2.32%)
Weekly Expected Move ±5.9%
$4
$4
$5
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Engineers Gate Manager LP Invests $709,000 in Taysha Gene Therapies, Inc. $TSHA
Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026
Here are the major earnings before the open Wednesday
Taysha Gene Therapies GAAP EPS of -$0.13 misses by $0.01
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
$TSHA stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G - GuruFocus
Taysha Gene Therapies president sells $1.25m in stock By Investing.com - Investing.com Nigeria
Insider Sale: President and Head of R&D of $TSHA Sells 200,000 Shares - Moomoo
Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop - simplywall.st
Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative? - simplywall.st
If You Invested $1,000 in Taysha Gene Therapies, Inc. (TSHA) - Stock Titan
Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA) - simplywall.st
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Biggest stock movers Thursday: AI chip stocks, WEN, SPRY, and more
Taysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
$TSHA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha prices $200M offering as closing nears June 26 - Stock Titan
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery - Yahoo Finance
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Four new Taysha hires get 714,700 RSUs and 468,600 options - Stock Titan
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility
Taysha (TSHA) Q1 2026 Earnings Transcript
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary
Taysha Gene Therapies Q1 Earnings Call Highlights
Earnings Scheduled For May 6, 2026
Taysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysis
Taysha Gene Therapies GAAP EPS of -$0.12 misses by $0.02
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Here are the major earnings before the open Wednesday
Taysha Gene Therapies Q1 2026 Earnings Preview
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $11.64 Consensus Target Price from Analysts
Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)
$TSHA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
This is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buy - MSN
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy - Yahoo Finance
TSHA (NASDAQ: TSHA) president sells 200K shares under 10b5-1 plan - Stock Titan
Taysha Gene Therapies (NASDAQ: TSHA) insider selling 200,000 shares - Stock Titan
Taysha Gene Therapies (TSHA) Is Up 5.6% After FDA Clears Rett Trial And Grants New Equity Awards - Has The Bull Case Changed? - simplywall.st
Aberdeen Group plc Purchases Shares of 1,021,063 Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.9% After Analyst Upgrade
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Four new Taysha hires get stock awards tied to 392,400 shares - Stock Titan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $11.09 Average Price Target from Brokerages
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus - simplywall.st
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha (TSHA) Q4 2025 Earnings Call Transcript
Taysha (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies GAAP EPS of -$0.34 beats by $0.02, revenue of $9.77M beats by $3.47M
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Earnings Scheduled For March 19, 2026
$TSHA ($TSHA) Releases Q4 2025 Earnings | TSHA Stock News - Quiver Quantitative
Rett syndrome gene therapy wins FDA clearance for child study, keeps Q2 timeline - Stock Titan
Here are the major earnings before the open Thursday
Taysha Gene Therapies FY 2025 Earnings Preview
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19